| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
The treatment of C6 and 9L glioma cells with tetraethylammonium (0.2-60 mM; 24-72 hours) reduces their proliferation in a dose- and time-dependent manner [1]. Apoptosis is markedly increased by tetraethylammonium (40 mM; 24-72 hours; C6 and 9L glioma cells) therapy [1]. Treatment of C6 and 9L glioma cells with 40 mM tetraethylammonium for 12–48 hours dramatically raises the Bax/Bcl-2 protein ratio in a time-dependent manner [1]. After adding 20 and 40 mM tetraethylammonium to C6 and 9L cells, intracellular ROS generation increased [1].
|
|---|---|
| ln Vivo |
In the rat colon and rectum, tetraethylammonium (1 mM, 3 mM, and 5 mM) dramatically enhances the amplitude and frequency of longitudinal and circular contractions. For ten days, tetraethylammonium was applied topically from the anus into the intestinal lumen. Rat colon and rectum histology was unaffected by tetraethylammonium at doses of 5 mM and 15 mM [2].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: Rat C6 and 9L glioma cells Tested Concentrations: 0.2mM, 2mM, 20mM, 40mM and 60mM Incubation Duration: 24 hrs (hours), 48 hrs (hours) and 72 hrs (hours) Experimental Results: Inhibited the proliferation of C6 and 9L cells in a dose- and time-dependent manner. Apoptosis Analysis[1] Cell Types: Rat C6 and 9L glioma cells Tested Concentrations: 40 mM Incubation Duration: 24 hrs (hours), 48 hrs (hours) and 72 hrs (hours) Experimental Results: Dramatically increased apoptosis in cells. Western Blot Analysis[1] Cell Types: Rat C6 and 9L glioma cells Tested Concentrations: 40 mM Incubation Duration: 12 hrs (hours), 24 hrs (hours), 48 hrs (hours) Experimental Results: The expression of Bax was markedly increased, while that of Bcl-2 demonstrated a decreasing trend 12 , 24 and 48 h. |
| References |
[1]. K B Yang, et al. Tetraethylammonium inhibits glioma cells via increasing production of intracellular reactive oxygen species. Chemotherapy. 2009;55(5):372-80.
[2]. Zhe Li, et al. Tetraethylammonium enhances the rectal and colonic motility in rats and human in vitro. Naunyn Schmiedebergs Arch Pharmacol. 2011 Aug;384(2):147-55. |
| Molecular Formula |
C8H20CLN
|
|---|---|
| Molecular Weight |
165.70
|
| CAS # |
56-34-8
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
[Cl-].[N+](C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (603.50 mM)
H2O: ≥ 100 mg/mL (603.50 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (603.50 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0350 mL | 30.1750 mL | 60.3500 mL | |
| 5 mM | 1.2070 mL | 6.0350 mL | 12.0700 mL | |
| 10 mM | 0.6035 mL | 3.0175 mL | 6.0350 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
